

Cite this: *Dalton Trans.*, 2016, **45**,
1398

Scandium(III) complexes of monophosphorus acid DOTA analogues: a thermodynamic and radiolabelling study with ^{44}Sc from cyclotron and from a $^{44}\text{Ti}/^{44}\text{Sc}$ generator†

R. Kerdjoudj,^a M. Pniok,^b C. Alliot,^{c,d} V. Kubiček,^b J. Havlíčková,^b F. Rösch,^e
P. Hermann^{*b} and S. Huclier-Markai^{*a,c}

The complexation ability of DOTA analogs bearing one methylenephosphonic (DO3AP) or methylenephosphinic (DO3AP^{PrA} and DO3AP^{ABn}) acid pendant arm toward scandium was evaluated. Stability constants of their scandium(III) complexes were determined by potentiometry combined with ^{45}Sc NMR spectroscopy. The stability constants of the monophosphinate analogues are somewhat lower than that of the Sc–DOTA complex. The phosphorus acid moiety interacts with trivalent scandium even in very acidic solutions forming *out-of-cage* complexes; the strong affinity of the phosphonate group to Sc(III) precludes stability constant determination of the Sc–DO3AP complex. These results were compared with those obtained by the free-ion selective radiotracer extraction (FISRE) method which is suitable for trace concentrations. FISRE underestimated the stability constants but their relative order was preserved. Nonetheless, as this method is experimentally simple, it is suitable for a quick relative comparison of stability constant values under trace concentrations. Radiolabelling of the ligands with ^{44}Sc was performed using the radioisotope from two sources, a $^{44}\text{Ti}/^{44}\text{Sc}$ generator and $^{44\text{m}}\text{Sc}/^{44}\text{Sc}$ from a cyclotron. The best radiolabelling conditions for the ligands were pH = 4, 70 °C and 20 min which were, however, not superior to those of the parent DOTA. Nonetheless, *in vitro* behaviour of the Sc(III) complexes in the presence of hydroxyapatite and rat serum showed sufficient stability of ^{44}Sc complexes of these ligands for *in vivo* applications. PET images and *ex vivo* biodistribution of the ^{44}Sc –DO3AP complex performed on healthy Wistar male rats showed no specific bone uptake and rapid clearance through urine.

Received 18th October 2015,
Accepted 24th November 2015

DOI: 10.1039/c5dt04084a

www.rsc.org/dalton

Introduction

On the way to personalized medicine, nuclear medicine offers both diagnostic tools and therapeutic drugs utilizing various radioisotopes. Until recently, most radiopharmaceuticals were designed to be used solely for either diagnostics or therapeutics. Radionuclides currently used for imaging, such as ^{68}Ga or ^{111}In , are different from those used for therapy, such as ^{90}Y or ^{177}Lu . One radionuclide would be used to image individual patient disease states and evaluate their receptor expression, metabolic rate, clearance and handling, and a second radionuclide would be used for therapy. Problems with this approach arose due to differences in the chemistry of the radionuclides themselves which have been shown to affect the overall pharmacology, in particular accumulation of the radiopharmaceuticals at target and non-target sites, resulting in an over- or underestimation of the dose to critical tissues and the dose being outside the optimum range of efficacy. In contrast,

^aLaboratoire Subatech, UMR 6457, Ecole des Mines de Nantes/CNRS/IN2P3/ Université de Nantes, 4 Rue A. Kastler, BP 20722, F-44307 Nantes Cedex 3, France. E-mail: sandrine.huclier@subatech.in2p3.fr; Fax: +33-251858452; Tel: +33-251858537

^bDepartment of Inorganic Chemistry, Faculty of Science, Universita Karlova, Hlavova 2030, CZ-12843 Prague 2, Czech Republic. E-mail: petr@natur.cuni.cz; Fax: +420-221951253; Tel: +420-221951263

^cARRONAX GIP, 1 rue Arronax, F-44817 Nantes Cedex, France

^dCRCNA, Inserm/CNRS/Université de Nantes, 8 quai Moncoussu, 44007 Nantes Cedex 1, France

^eInstitute of Nuclear Chemistry, Johannes-Gutenberg-University of Mainz, Fritz-Strassmann-Weg 2, D-55128 Mainz, Germany

† Electronic supplementary information (ESI) available: Experimental details on potentiometry, FISRE and NMR measurements, figures with NMR and titration data, FISRE isotherms, experimental details and figures for challenge studies, table of specific activities of labelled ligands. See DOI: 10.1039/c5dt04084a



using the same metal to perform both diagnosis and therapy would result in a better determination of the absorbed dose and would give a better indication of the therapeutic activity necessary to administer the dose. Such a radiopharmaceutical pair utilizing diagnostic and therapeutic radioisotopes is called “theranostics”.¹

Among the radionuclides available, there is significant interest in the therapeutic radioisotope ^{47}Sc (β^- , $\tau_{1/2}$ 3.35 d, E_β 0.143 (68%) and 0.204 MeV (32%); γ , E_γ 159.4 keV, 68%) as it matches with the positron-emitting ^{44}Sc (β^+ , $\tau_{1/2}$ 3.97 h, E_β 0.63 MeV, 94.3%) or ^{43}Sc (β^+ , $\tau_{1/2}$ 3.89 h, E_β 0.344 MeV (17.2%) and 0.508 MeV (70.9%)) and, thus, they form an ideal theranostic pair. The potential of ^{47}Sc for nuclear medicine has been already investigated.^{2–4} The possibility of ^{47}Sc production by neutron irradiation of ^{47}Ti and consecutive solid-phase extraction chromatography has been evaluated.⁵ Very recently, the feasibility of photonuclear production of ^{47}Sc from ^{48}Ca or $^{47}\text{Ca}/^{47}\text{Sc}$ generators has been studied.^{5,6} Due to its dominant positron emission, ^{44}Sc is very suitable for PET imaging. Its half-life perfectly matches the pharmacokinetics of small molecules or (oligo)peptides. In addition to two collinear γ rays produced by annihilation, ^{44}Sc offers a third γ ray suitable for three-photon coincidence imaging which may further increase resolution of the current PET imaging.⁷ In addition, the radioisotope can be produced together with its long-lived isomeric excited nucleus, $^{44\text{m}}\text{Sc}$ (γ , $\tau_{1/2}$ 2.44 d, 98.8%, E_γ 270.9 keV), decaying to ^{44}Sc with soft γ emission. The half-life of $^{44\text{m}}\text{Sc}$ matches the *in vivo* pharmacokinetics of antibodies and, due to its low-energy transition (recoil energy only 0.89 eV), it can serve as an *in vivo* generator of ^{44}Sc as the daughter ^{44}Sc stays inside the chelator after the decay of the parent $^{44\text{m}}\text{Sc}$ nucleus.⁸ The $^{44\text{m}}\text{Sc}/^{47}\text{Sc}$ theranostic pair with both radionuclides having similar half-lives is very suitable for radiopharmaceuticals utilizing antibodies or their fragments and, thus, they form a unique and very promising theranostic pair for cancer treatments. Utilizations of the Sc-based theranostic pairs can be spread from antibody radioimmunotherapy (the $^{44\text{m}}\text{Sc}/^{47}\text{Sc}$ pair) to treatments with labeled oligopeptides or small molecules (the $^{44}\text{Sc}/^{47}\text{Sc}$ pair).

^{44}Sc can be produced by a generator employing ^{44}Ti as a long-lived parent radioisotope.^{9,10} The radioisotope can be also produced in most medical cyclotrons designed for ^{18}F production.¹¹ The ARRONAX cyclotron produces the $^{44\text{m}}\text{Sc}/^{44}\text{Sc}$ pair from an enriched $^{44}\text{CaCO}_3$ target *via* the deuteron production route¹² which seems to be a promising route to obtain non-carrier-added (NCA) ^{44}Sc with an optimized $^{44\text{m}}\text{Sc}/^{44}\text{Sc}$ ratio. Other production routes allow a better $^{44\text{m}}\text{Sc}/^{44}\text{Sc}$ ratio by bombarding a ^{45}Sc target^{13–15} leading to a carrier-added product and it is a major drawback for the production of radiopharmaceuticals.

Metallic radioisotopes utilized in nuclear medicine must be tightly bound in a complex to avoid non-specific deposition in tissues. These complexes must exhibit a high thermodynamic stability, a high selectivity for a particular metal ion, a fast complexation of the metallic radioisotopes, kinetic inertness as well as an ability to be conjugated to a biological vector

molecule (bifunctional ligands). The design of new radiopharmaceuticals is a viable multidisciplinary field involving physics, chemistry, biology and medicine.^{16–22}

Scandium is a cousin of lanthanides but with some differences. Sc(III) is smaller than Ln(III) (thus, being harder and with a higher preference for hard oxygen donor ligands) and it prefers donor numbers from six to eight. However, the chemistry of trivalent scandium is much less developed than that of trivalent lanthanides.²³ Mostly, multidentate ligands already used in Gd(III)-based MRI contrast agents as well as for radiolanthanides, *i.e.* derivatives of DTPA (DTPA = diethylenetriamine-*N,N,N',N'',N'''*-pentaacetic acid) or DOTA (DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), are the first choice to bind the ion. It has been shown that DOTA derivatives are suitable ligands for scandium radioisotopes.²⁴ Their oligopeptide,^{10,25–29} antibody^{30,31} or other^{32,33} conjugates have been investigated for complexation of the scandium radionuclides.

Recently, we have investigated the chemistry of Sc(III)–DTPA and Sc(III)–DOTA complexes in detail.³⁴ The study confirms that DOTA is a very suitable chelator for trivalent scandium. Efficient radiolabeling of DOTA with $^{44\text{m}}/^{44}\text{Sc}$ requires elevated temperatures (>70 °C).⁸ For oligopeptides, such a high temperature is not a critical parameter. However, antibodies or their fragments need a much lower labelling temperature (mostly below 37 °C) to preserve their immunoreactivity. Slow formation kinetics of DOTA-like chelators remains an important obstacle limiting their use in some radiopharmaceuticals. Therefore, ligands permitting formation of complexes at much lower temperatures to label antibody conjugates are sought.

Scandium(III) is a “harder” metal ion than trivalent lanthanides and oxygen atoms in derivatives of phosphoric acid have a “harder” character than those in the carboxylate group. Thus, phosphonic (R– PO_3H_2) or phosphinic ($\text{R}_2\text{PO}_2\text{H}$) acid pendants may alter ligand behaviour in the desired direction.³⁵ Such DOTA derivatives form thermodynamically stable and kinetically inert complexes with somewhat enhanced complexation kinetics.^{36–38} Their complexes/conjugates are stable *in vivo* and show good pharmacokinetic properties due to their high hydrophilicity.^{39–41} Trivalent gallium is a similar very




Fig. 1 Structures of ligands discussed in this work.



hard metal ion and phosphinic acid derivatives of NOTA (NOTA = 1,4,7-triazacyclononane-1,4,7-triacetic acid) showed much faster labeling with ^{68}Ga as compared to the parent ligand.^{42,43}

Therefore, monophosphorus acid DOTA analogs, DO3AP, DO3AP^{ABn} and DO3AP^{PrA} (Fig. 1) were considered as better ligands than DOTA. Solution investigations of their complexes were complemented by radiochemical studies with non-carrier-added (NCA) ^{44}Sc from two sources, a $^{44}\text{Ti}/^{44}\text{Sc}$ generator and from an ARRONAX cyclotron, and by *in vivo/in vitro* evaluation of the radiolabelled complexes.

Experimental

General

The phosphorus acid DOTA analogues, DO3AP^{PrA}, DO3AP and DO3AP^{ABn} (prepared as hydrates according to elemental analysis) were synthesized according to the literature.^{37,44,45} DOTA (reagent grade) was obtained from Macrocylics. Analytical grade (conc. aq. HCl, conc. aq. ammonia, MeOH, EtOH, HNO₃, ammonium acetate) or pure reagent grade (all other chemicals) reagents were obtained commercially and were used as received unless otherwise specified. Deionized water (18.2 MΩ cm⁻¹; Milli-Q, Millipore) was used throughout the work. Solid-phase extraction resin based on DGA (*N,N,N',N'*-tetra(*n*-octyl)diglycolamide; Triskem), cation AG1-X8 (200–400 mesh, Cl⁻-form; Bio-Rad), anion AG50W-X8 (200–400 mesh, H⁺-form; Sigma) exchangers, and Chelex-100 (imino-diacetate functionalized resin; Sigma) were purchased. The concentrations of stable scandium together with potential metals present in the solutions were analysed by ICP-AES (ThermoFischer ICAP 6500 DUO ICP-AES). The wavelengths for each element were selected in order to give the best relative emissions and to prevent interferences. To calibrate the ICP-AES, commercially available single- and multi-element standards (~10 ppm, SCP Science) were used in dilute nitric acid (1% w/w). The acidic solutions of the radioisotope batches were collected and were diluted in aq. HNO₃ (1% w/w) prior to the analysis.

Production of ^{44}Sc

Cyclotron-produced $^{44m/44}\text{Sc}$. The procedure of $^{44m/44}\text{Sc}$ production at the Arronax cyclotron has been described elsewhere.¹² Briefly, an irradiated natural CaCO₃ (500 mg) target was dissolved in aq. HCl (4 M, 10 mL) and the resulting solution was loaded onto a column filled with DGA resin. Then, the column was washed with aq. HNO₃ (1 M, 10 mL) to remove all other metal ions. Finally, ^{44}Sc was eluted by aq. HCl (0.1 M, 400 μL) and the solution was evaporated to dryness. Aq. HCl (0.1 M) was added to obtain a $^{44}\text{Sc(III)}$ -chloride solution with the resulting activity >100 MBq. The solution of $^{44m/44}\text{Sc}$ was analysed by using a γ -spectrometer (Ortec-Ametek, France). The energies of the rays were 271.1 keV and 1157 keV for ^{44m}Sc and ^{44}Sc , respectively, with a branching ratio of 98.8% and 99.9%. Radionuclidic analysis through gamma spectrometry

(HPGe, Ortec) showed that the final solutions contained only $^{44/44m}\text{Sc}$. No other significant radionuclides could be detected, even after a decay time corresponding to several half-lives of radios scandium. ICP-AES analyses of the eluate gave a value which is below the detection limit for stable scandium resulting in a specific activity higher than 50 MBq μmol⁻¹. The other major metallic contaminants were Fe and Al. In the ^{44}Sc batches, the total concentration of both elements Fe/Al was always 1.14 ± 0.66 ppm.

Generator-produced ^{44}Sc . The procedure to obtain ^{44}Sc by this route has been described elsewhere.¹⁰ Briefly, from ^{44}Ti adsorbed onto a column filled with AG1-X8 anion exchange resin, ^{44}Sc was eluted with aq. 0.005 M H₂C₂O₄ in aq. 0.07 M HCl (20 mL). The eluate was directly post-processed on a miniaturized column filled with AG50W-X8 cation exchange resin (~50 mg) where ^{44}Sc was quantitatively adsorbed on-line and then successively eluted using aq. 0.25 M ammonium acetate buffer (pH 4, 2–3 mL). This ^{44}Sc solution has a small volume and is free of competing oxalates. Radioactivity was determined with a dose calibrator Aktivitätsmessgerät M2316 (Messelektronik, Dresden GmbH). The absolute radioactivity and purity of ^{44}Sc was measured by γ -ray spectrometry with a high-purity germanium (HPGe) well counter detector using both 1157.2 and 1499.4 keV γ -lines.

Potentiometry

Potentiometric titrations were performed by a general method described elsewhere:^{34,36} 25 °C, $I = 0.1$ M (NMe₄)Cl, starting volume 5 mL (ligands) or 1 mL (complexes), ligand concentration 0.004 M, ligand : Sc molar ratio 1 : 0.95, PHM 240 pH-meter, 2 mL ABU901 autoburette and GKB2401B combined electrode (glass/Ag–AgCl, all Radiometer), $pK_w = 13.81$. Electrode calibration by strong acid–strong base titration was performed before each titration to give a pair calibration/titration which was used for calculations of the constants; the procedure gives a reliable pH even at pH below 2 and above 12. To obtain very acidic protonation constants of DO3AP^{PrA} and DO3AP^{ABn} which were necessary for the correct determination of Sc(III) complex stability constants, the ligands were titrated in the pH range 1.4–11.8 with electrode calibration performed in the pH range 1.5–11.8 (~50 points per titration, four titrations per sample). As complexation equilibria in Sc(III)–ligand systems were slow (time to reach full equilibrium was six days; checked by NMR), the titrations were carried out by the *out-of-cell* method;^{34,36} pH range 1.4–5.5, 23–25 points per titration, two parallel titrations. To help with the determination of the first protonation constant of the complexes and enable correct fitting of all equilibrium data for the Sc(III)–DO3AP^{ABn} and –DO3AP^{PrA} systems, the acid–base titrations of the pre-formed complexes were performed.⁴⁶ Stock solutions of the ligands (0.02 M) and ScCl₃ (0.05 M) were mixed in ampoules (L : Sc molar ratio 1 : 0.95, $c_L = 0.006$ M in the final samples) and a stock solution of (NMe₄)OH was added (98% necessary for complete neutralization of the added ligand amount). The ampoule was flame-sealed, heated at 90 °C in an oven for 24 h to ensure complete complexation of the Sc(III) ion, cooled to



room temperature and opened. The solution was pipetted into a titration vessel, water and excess of HCl/(NMe₄)Cl solution were added (to ensure acidic starting pH and 0.1 M ionic strength), and the solution (starting volume 5 mL) was immediately titrated by (NMe₄)OH stock solution (pH range 1.7–12, ~40 points per titration, 4 parallel titrations, the complex concentration ~0.003 M). Mathematical treatment of all equilibrium data (together with the NMR titration data, see below) was done with the OPIUM program package.⁴⁷ The constants are concentration constants and were calculated as overall protonation/stability constants β_{him} defined generally as $\beta_{him} = [H_nLM]/([H]^n \cdot [L] \cdot [M])$; charges are omitted. The calculated overall protonation/stability constants (with standard deviations given directly by the program) are presented in the ESI (Tables S1 and S2†). Throughout the text, pH means $-\log[H^+]$.

NMR measurements

The ⁴⁵Sc (97.15 MHz) and ³¹P{¹H} (161.91 MHz) NMR spectra were recorded on Varian UNITY Inova 400. All experiments, unless stated otherwise, were carried out in 5 mm NMR tubes at 25.0 °C. The ³¹P NMR chemical shifts were referenced to 85% aq. H₃PO₄ ($\delta_p = 0.0$ ppm). The ⁴⁵Sc NMR chemical shifts were measured with respect to 0.1 M Sc(ClO₄)₃ in 1 M aq. HClO₄ ($\delta_{sc} = 0.0$ ppm), 0.01 M [Sc(ox)₄]⁵⁻ ($\delta_{sc} = 8.31$ ppm)³⁴ or 0.01 M [Sc(tmu)₆](ClO₄)₃ in CH₃NO₂ (tmu = *N,N,N',N'*-tetramethylurea; $\delta_{sc} = -53.3$ ppm)⁴⁸ as external standards in the insert tube. The equation $pD = pH + 0.4$ (pH is a standard pH-meter reading) was used for D₂O solutions.

Samples for NMR titrations were prepared similarly to the *out-of-cell* titration as given above and analogously to the previous paper.³⁴ Stock solutions of the ligands, ScCl₃, HCl, KCl (if necessary), and water were mixed into tubes (final $c_L = 0.004$ M, L : Sc molar ratio 1 : 0.95, $V_0 = 1$ mL; $I = 0.1$ M (H,K) Cl, with no control of the ionic strength at pH < 1.1) to obtain pH in the range 0.5–1.3 and the tubes were tightly closed (12–15 titration points); the equilibration time was seven days at room temperature. Species abundance in each tube (*i.e.* the titration point) was determined by ⁴⁵Sc NMR measurements. Two parallel titrations were carried out. To determine the equilibration time, other samples were prepared as above at three pHs, the samples were left at room temperature and ⁴⁵Sc NMR spectral changes with time were followed.

Samples for equilibrium studies with the Sc(III)–DO3AP system were prepared by mixing stock solutions of DO3AP, ScCl₃, 17% or 5% aq. HCl, 1.1 M or 0.2 M HCl, 0.2 M KCl (if necessary), and water into tubes (conditions as above). The solutions were left to equilibrate for at least seven days at room temperature and pH values were determined as above. Job's method was employed to determine stoichiometry of the *out-of-cage* species in the Sc(III)–DO3AP system. Each sample was prepared in a vial by mixing 0.1 M aq. ScCl₃ and 0.1 M aq. DO3AP stock solutions with 1 M aq. HCl (final volume 1 mL, pH 0.22, $c_{Sc} = 4$ –20 mM, $c_{Sc+L} = 40$ mM, 7 points, equilibration time seven days). To determine protonation constants of

[Sc(DO3AP)]²⁻ isomeric species, a pre-prepared complex was dissolved in H₂O in a 10 mm NMR tube and the desired pH was adjusted with aq. HCl or aq. (NMe₄)OH ($c_{ScL} \sim 0.01$ M, pH range 4.15–7.67, 26 points). The pH was determined by a freshly calibrated (three buffers) combined pH electrode fitting the NMR tube.

To characterize the [Sc(DO3AP^{PrA})]²⁻, [Sc(DO3AP^{ABn})]⁻ and [Sc(DO3AP)]²⁻ complexes, their solutions were prepared by dissolving the appropriate ligand (0.05 mmol), ScCl₃·6H₂O (0.055 mmol) in water (1 mL) and adjusting the solution pH to ~7 with solid Li₂CO₃. Then, the solutions were stirred in sealed vials at 90 °C for 2 h. Excess of Sc(III) precipitated as white Sc(III)–carbonate/hydroxide and was filtered off with a syringe filter and the filtrate was evaporated to dryness. The solid was dissolved in D₂O (0.5 mL) to obtain a solution with the complex concentration ~0.1 M.

Free-ion selective radiotracer extraction (FISRE) method

An aliquot of the Chelex-100 chelating resin was mixed with bulk aq. solution containing ⁴⁵Sc to give a final concentration of the isotope 10⁻⁵ M. To prevent the potential interference of nitrate ions on the distribution behaviour of the metallic content, aliquots of standard solutions were transferred into a dry Teflon beaker pre-cleaned with ultrapure aq. HNO₃ (2% w/w). Then, they were evaporated to dryness and recovered in a suitable solution three times. The ligand stock solution was added to reach a final ligand concentration ranging from 10⁻⁷ to 10⁻³ M. All measurements were performed at ionic strength $I = 0.1$ M NaCl. The pH of the suspension was adjusted to pH = 2.6; 2.5 and 2.3 according to the ligand (DO3AP, DO3AP^{PrA} or DO3AP^{ABn}, respectively). These pH values were estimated by taking into account stability constant values ($\log K_{ScL}$) obtained from the equilibrium data. As the distribution coefficients were calculated as a function of dried resin mass, humidity content was determined by drying five samples of each pre-conditioned resin in an oven at 105 °C. The final distribution coefficients were calculated on the basis of the arithmetic averages of replicate analyses (at least triplicate analysis). The resin concentration (in g mL⁻¹) was chosen for each batch to minimize the global uncertainty of the partition coefficient. The reproducibility of $\log K_d$ was better than 5%.

The resulting suspension was equilibrated for 24 h and the pH was re-adjusted, if necessary. In preliminary experiments, the sufficient equilibration time was found to be six days for all the systems. Solid and liquid phases were separated by sedimentation. Aliquots (1 mL) of the supernatant were taken for ICP-AES analysis. Scandium concentrations were determined and experimental K_d values were plotted as a function of the total ligand concentration in the solutions. These dependences were used for stability constant determinations. To check the potential presence of protonated complexes, other sets of experiments were performed at fixed ligand concentrations (10⁻³ M) in the pH range 2–7 utilizing the same protocol as described above.



Radiolabelling with ^{44}Sc

^{44}Sc from a $^{44}\text{Ti}/^{44}\text{Sc}$ generator. Labeling of monophosphorus acid DOTA analogues and DOTA with ^{44}Sc was performed by mixing of the ligand stock solution with the post-processed ^{44}Sc eluate in 0.25 M ammonium acetate buffer (pH 4.0) and heating the mixture in an oil bath. Several parameters were followed in repeated experiments (3–4 times): temperature, pH of the reaction mixtures and the ligand concentration (precisely, ligand molar excess over the radioisotope molar amount). The influence of temperature and incubation time on the reaction yield was investigated by heating solutions containing ^{44}Sc (16.2 MBq, $[\text{Sc}^{3+}] \sim 5.8 \times 10^{-13}$ M) and 20 nmol of the ligand (DOTA, DO3AP or DO3AP^{ABn}) at 40 °C, 70 °C and 90 °C for up to 30 min. To determine the effect of pH, 4 M aq. HCl or 4 M aq. NaOH was added dropwise to a mixture (3 ml) of the ligand (20 nmol) and ^{44}Sc (1.3 MBq, $[\text{Sc}^{3+}] \sim 4.5 \times 10^{-14}$ M) in 0.25 M aq. ammonium acetate buffer to obtain the desired pH (2–6) and the solutions were then heated at 90 °C for 30 min; the pH was measured before and after the heating and no significant change was observed. The effect of ligand concentration/excess was evaluated with the quantity of the ligand being varied from 1 to 30 nmol and the solutions were heated (70 °C, pH = 4, 30 min). Radiolabeling was checked by thin-layer chromatography (TLC Silica-gel 60 plates, Merck). The plates were developed by 0.24 M aq. sodium citrate buffer (pH = 4). Quantitative distribution of radioactivity on TLC plates was measured using an electronic autoradiography system (Instant Imager, Packard Canberra). The uncomplexed ^{44}Sc moved with $R_f = 0.8$, whereas the ^{44}Sc complexes stayed on start with $R_f = 0$.

$^{44}\text{mSc}/^{44}\text{Sc}$ from cyclotron (Arronax). For the $^{44}\text{m}/^{44}\text{Sc}$ mixture, the influence of temperature and pH on labelling yields was investigated as described above. To follow the influence of the ligand concentration/excess, lower ligand amounts had to be used (if compared with the ^{44}Sc from the generator); they varied from 24 to 240 pmol (pH 4, 70 °C, 30 min). Radiolabeling was followed by spotting $3 \times 1 \mu\text{L}$ onto a TLC Flex Plate (silica gel 60A, IF-254, 200 μm , Merck) followed by elution with conc. aq. $\text{NH}_3/\text{H}_2\text{O}/\text{MeOH}$ 2/1/1 (v/v/v). The resulting TLC plate was counted for 10 min on an autoradiographic system (Cyclone, Perkin Elmer). Under these conditions, the ^{44}Sc complexes moved with $R_f = 0.9$ whereas the unchelated ^{44}Sc had $R_f = 0$.

In vitro and *in vivo* experiments

The *in vitro* challenge studies (stability in serum, hydroxapatite adsorption) were performed by standard procedures and details are given in the ESI.†

Animal studies were carried out in accordance with the guidelines of the French law on Animal Studies. Biodistribution of the ^{44}Sc -DO3AP complex was followed in four healthy Wistar rats injected intravenously with ^{44}Sc -DO3AP solution (100 μL , 1 MBq). The animals were imaged at selected time intervals, then sacrificed and dissected. The rats were sacrificed at 30 min and 1 h, two rats per time point. Organs were

collected, weighed, counted on a gamma counter, and the percentage of injected dose per gram of tissue (% ID per g) was calculated. PET images were acquired using a Siemens Inveon micro PET/CT instrument.

Results and discussion

Characterization of the Sc(III) complexes in solution

Structures of the *in-cage* complexes in solution were determined by ^1H , $^{31}\text{P}\{^1\text{H}\}$ and ^{45}Sc NMR measurements. In all cases, ^1H NMR spectra were very complicated due to the non-equivalence of all protons in a rigid structure. The $^{31}\text{P}\{^1\text{H}\}$ NMR spectra showed the presence of two signals (Fig. 2). On the basis of a number of data for lanthanide(III) complexes of DOTA-like ligands, such an observation can be explained by the presence of two isomeric complexes having square antiprismatic (SA) and twisted square antiprismatic (TSA) arrangements. These isomers have been observed for lanthanide(III) complexes of the title ligands.^{44,45} It is surprising as only one isomer, SA, was observed in solution for the $[\text{Sc}(\text{DOTA})]^-$ complex,⁵⁰ although both isomers have been found in the solid state.^{34,50} It was observed that the ^{31}P NMR chemical shift and relative abundance of the TSA/SA isomers of the Sc(III)-DO3AP complex is changed in the pH range 4–7. Such behaviour has been observed for lanthanide(III) complexes of DO3AP⁴⁴ and is connected with protonation of the coordinated phosphonate group. Thus, $^{31}\text{P}\{^1\text{H}\}$ NMR spectra were recorded over the pH range (Fig. S4†) and used for calculation of protonation constants for each complex isomer. The




Fig. 2 ^{45}Sc and $^{31}\text{P}\{^1\text{H}\}$ NMR spectra of $[\text{Sc}(\text{DO3AP})]^{2-}$ (A), $[\text{Sc}(\text{DO3AP}^{\text{PrA}})]^{2-}$ (B) and $[\text{Sc}(\text{DO3AP}^{\text{ABn}})]^-$ (C) in D_2O (0.1 M, pD = 7.1).



results, $\log K_a$ 5.33 and 5.53, correspond well to the potentiometric data (see below) and the values are similar to those found for the Ln(III) analogues.⁴⁴ The isomer ratio did not change with pH for the complexes of the phosphinate ligands.

The ⁴⁵Sc NMR spectra (Fig. 2) recorded in 0.1 M solutions of pre-prepared complexes showed very broad peaks 87 ppm ($\omega_{1/2} \sim 5200$ Hz), 87 ppm ($\omega_{1/2} \sim 5700$ Hz) and 90 ppm ($\omega_{1/2} \sim 7200$ Hz) for the [Sc(DO3AP)]²⁻, [Sc(DO3AP^{PRA})]²⁻ and [Sc(DO3AP^{ABn})]⁻ complexes, respectively. The values are similar to those observed for [Sc(DOTA)]⁻ ($\delta_{Sc} \sim 100$ ppm, $\omega_{1/2} \sim 4300$ Hz)³⁴ also confirming the formation of the *in-cage* complex for all ligands.

Equilibrium studies

For the Sc(III)-DO3AP^{ABn} and -DO3AP^{PRA} systems, it was found that equilibrium at pH > 1.8 (*i.e.* formation of *in-cage* complexes, see below) is established during several days and the rate of complexation is faster with a higher pH (Fig. S1†). Equilibria in very acidic solutions (formation of *out-of-cage* complexes) were established almost immediately. Similarly to the Sc(III)-DOTA system, the Sc(III)-aqua complex disappeared above pH ~ 1.8 . However, some complex formation started even at pH 0–0.5 (Fig. S2†) as indicated by a broad ⁴⁵Sc NMR peak (~ 35 ppm). This chemical shift suggests a purely oxygen coordination sphere. It can be facilitated by the presence of a phosphinic acid group able to bind metal ions even in very acidic solutions (see also below). Therefore, the species can be assigned as *out-of-cage* complexes where the Sc(III) ion is coordinated by oxygen atom(s) from one or more pendant arms of the ligands. Once the *in-cage* complexes (the Sc(III) ion is sandwiched between N4 and O4 planes as in the [Sc(DOTA)]⁻ complex⁵⁰) are formed, the ⁴⁵Sc NMR signal of the *out-of-cage* complexes starts to broaden and decreases in intensity and, finally, no ⁴⁵Sc NMR signal is observed (due to a low concentration of the complexes in these titration experiments). In parallel, two broad closely located ³¹P{¹H} NMR signals assignable to the Sc(III)-bound phosphinate group in the isomeric *in-cage* complexes start to be observed. To quantify the abundance of the Sc(III)-aqua ion for stability constant determination (see below), [Sc(tmu)₆]³⁺ had to be used as the secondary standard⁴⁸ as other standards³⁴ overlapped with the signal of the *out-of-cage* species.

The behaviour of the Sc(III)-DO3AP system was analogous to that observed for the Sc(III)-DO3AP^{ABn} and -DO3AP^{PRA} systems only at pH above ~ 3.8 ; no ⁴⁵Sc and two ³¹P{¹H} NMR peaks were observed confirming the formation of the *in-cage* complex (Fig. 3). From potentiometric titrations in this pH range, only the constant corresponding to protonation of the coordinated phosphonate group in the *in-cage* complex, $\log K_a$ 5.29, could be determined (Table S2†). However, unexpected results were obtained for the Sc(III)-DO3AP system in more acidic solutions. Here, other peaks appeared in both NMR spectra: $\delta_{Sc} \sim 23$ ppm, and $\delta_P -8.3$ ppm (Fig. 3). The ⁴⁵Sc NMR signal of the Sc(III)-aqua complex starts to be observable below pH ~ 0.8 . Surprisingly, the signal at $\delta_{Sc} \sim 23$ ppm was present even in extremely acidic solutions (up to 1 : 1 aq. HCl). Most




Fig. 3 ⁴⁵Sc (A) and ³¹P{¹H} (B) NMR spectra of equilibrated solutions prepared by mixing ScCl₃ and DO3AP ($c_{Sc} = c_L = 0.004$ M). The given pH values are those of the equilibrated solutions.

probably, the NMR signal can be assigned to an *out-of-cage* complex species where at least the protonated phosphonate group (and, possibly, the acetate group(s) as well) is bound to the scandium(III) ion. Such a coordination mode of the phosphonate group has been observed with metal ions (*e.g.* trivalent lanthanides) even under highly acidic conditions.^{51,52} The overall stoichiometry of the Sc(III)-DO3AP species present in the acidic solutions can be roughly estimated as Sc : L = 1 : 2 from a Job-like plot of NMR signal intensities (Fig. S3†) and, overall, the speciation is rather complicated. Unfortunately, such solution behaviour (*i.e.* not determinable correct Sc/DO3AP stoichiometry as well as the number of protons in the species) precluded determination of the Sc(III)-DO3AP complex stability constants as the system is too complex to be modeled by equilibrium constant calculations.

The stability constants were determined by a combination of three techniques, ⁴⁵Sc NMR, out-of-cell and direct (in-cell) potentiometry (for more detailed discussion, see the ESI†). The stability constants are presented in Table 1 and the experimentally determined overall stability constants are given in Table S2.† The corresponding distribution diagrams are shown in Fig. 4. The Sc(III) complexes of DO3AP^{ABn} and DO3AP^{PRA} are more stable than their lanthanide(III) complexes ($\log K_{LuL}$ 24.0 and 25.5, respectively)³⁷ but less stable than the [Sc(DOTA)]⁻ complex ($\log K_{ScL}$ 30.79).³⁴ The difference in stability constants between the lutetium(III) and scandium(III) complexes is similar for all ligands. The first Sc(III) complex protonation constants, corresponding to the protonation of amino or



Table 1 Equilibrium stability constants of scandium(III) complexes of DO3AP, DO3AP^{ABn} and DO3AP^{PrA} and their comparison with those of DTPA and DOTA^{3−} (25 °C, I = 0.1 M (NMe₄)Cl)

Equilibrium ^a	DO3AP ^{ABn}	DO3AP ^{PrA} ^b	DO3AP ^c	DOTA	DTPA
L + Sc ⇌ [Sc(L)]	27.03	28.31		30.79	27.43
[Sc(L)] + H ⇌ [Sc(HL)]	5.17	4.18	5.29	1.0	1.36
[Sc(HL)] + 2H ⇌ [Sc(H ₃ L)]	3.96	4.35			
[Sc(OH)(L)] + H ⇌ [Sc(L)] + H ₂ O	12.83	12.03			12.44

^a Charges are omitted for clarity. ^b The most acidic protonation constants of DO3AP^{PrA} were re-determined: log K₅ 2.94 and log K₆ 1.54 (Table S1).

^c Other constants could not be determined (see text).




Fig. 4 Distribution diagram for the Sc³⁺-DO3AP^{ABn} system (A) and the Sc³⁺-DO3AP^{PrA} system (B). c_{Sc} = c_L = 0.004 M. The abundance of free Sc³⁺ ion (□) was determined by ⁴⁵Sc NMR spectroscopy.


carboxylate groups in the phosphorus side chain, are almost identical to those of lutetium(III) complexes.³⁷ The next two protons are attached to the ring nitrogen atoms with the formation of *out-of-cage* complexes where the scandium(III) ion is bound only to pendant arm oxygen atom(s). Such a chemical model has already been suggested for lanthanide(III)-DO3AP systems³⁶ and such *out-of-cage* species diprotonated on ring amines have been observed for lanthanide(III) complexes in the solid state as well as in solution.^{41,53} The very high abundance of the triprotonated species (Fig. 4) can be caused by a strong preference of trivalent scandium for hard phosphinate oxygen donors in the *out-of-cage* species.

As stability constants of the Sc(III)-DO3AP complex cannot be determined by the above method, a competition method with trivalent ytterbium (as the metal ion with a very high stability constant with DO3AP, log K_{YbL} ~ 28.5)³⁶ as well as transchelation with DTPA were tested. In both cases, the determination failed due to problems with too slow kinetics of the transmetallation or transchelation.

Determination of stability constants under trace concentrations

Another technique, the Free Ion Selective Radiotracer Extraction (FISRE) method⁵⁴ was employed to determine stability constants in trace (micromolar) concentrations of the ligands. The technique uses a chelating ion exchanger (here, Chelex-100 containing imino-diacetate groups was used) as a competing “ligand”. The chelating resin competes with the ligands for the Sc³⁺ ion and the speciation is determined by solid/liquid separation. Recently, the method has been used for the determination of thermodynamic stability of metallo-radiopharmaceuticals containing Y(III).⁵⁵ The technique has been also used to estimate stability constants of scandium(III) complexes with EDTA, DTPA, NOTA and DOTA.²⁴

Adsorption of the free Sc³⁺-aqua ion on imino-diacetate chelating groups ($\overline{X-H}$) can be described by the following equilibrium (eqn (1)):



The overlined species refer to the species present on the resin (adsorbed species). The electroneutrality of each phase is required. Stability constants could be estimated by fitting dependence of the distribution coefficient (K_d) of Sc(III) between the resin and the supernatant on the total ligand concentration in the supernatant. If both the ligand and the exchange resin are used in a large excess in comparison with the initial Sc concentration, K_d values could be expressed as eqn (2):

$$K_d = \frac{K_{\text{abs}}[\overline{X-H}]^3}{[\text{H}^+]^3 \alpha_{\text{Sc(L,OH)}}} \quad (2)$$

where K_{abs} is the equilibrium constant for binding scandium(III) to the resin. $\alpha_{\text{Sc(L,OH)}}$ is the complexation coefficient of Sc³⁺ that is defined as the ratio between the total aqueous scandium concentration [Sc(III)]_{sol} and the Sc³⁺-aqua ion concentration [Sc³⁺] by eqn (3):

$$\alpha_{\text{Sc(L,OH)}} = \frac{[\text{Sc}^{3+}]_{\text{sol}}}{[\text{Sc}^{3+}]} = 1 + \sum_{h,l} \frac{[\text{ScH}_h\text{L}_l]}{[\text{Sc}^{3+}]} = 1 + \sum_{h,l} \beta_{h,l} [\text{L}]^l [\text{H}^+]^h \quad (3)$$






Fig. 5 The Sc(III)–ligand isotherms obtained by the FISRE method: DO3AP (full line); DO3AP^{PrA} (dashed line) and DO3AP^{ABn} (dotted line). The lines correspond to the fitting as explained in the ESI.† Solution pH and concentration of the Chelex resin were adjusted for each batch to minimize the global uncertainty of the partition coefficient ($l = 0.1$ M NaCl).

Table 2 Equilibrium constants ($\log K$) of scandium(III)–DO3AP, –DO3AP^{ABn} and –DO3AP^{PrA} complexes as determined by the FISRE method

Equilibrium ^a	DO3AP	DO3AP ^{ABn}	DO3AP ^{PrA}
$L + Sc \rightleftharpoons [Sc(L)]$	27.75(8)	25.51(4)	25.75(8)
$H + L + Sc \rightleftharpoons [Sc(HL)]$	33.20(3)	29.20(6)	30.02(8)
$[Sc(L)] + H \rightleftharpoons [Sc(HL)]$	5.45	3.69	4.27

^a Charges are omitted for clarity.

where $\beta_{h,l}$ is the overall stability constant of the complexes in question, $[ScH_hL_l]$, as defined by eqn (4):

$$\beta_{h,l} = \frac{[ScL_lH_h]}{[Sc] \cdot [L]^l \cdot [H]^h} \quad (4)$$

As $\alpha_{Sc(L,OH)}$ is a function of the ligand protonation constants and stability constants of the corresponding Sc(III) complexes, the stability constants could be calculated by fitting of the K_d values determined at various ligand excesses and at various solution pH values according to eqn (2). For the full set of equations and more explicit explanation of the method, see the ESI.†

Transchelation kinetics of macrocyclic ligands is generally slow. Therefore, the equilibration time was at least six days. The experimental data are depicted in Fig. 5 and S5.† To obtain a good fit of the data obtained for various pH values, not only $[Sc(L)]$ but also $[Sc(HL)]$ species had to be included in all systems (for a comparison of different models, see Fig. S5†). The results are summarized in Table 2. The values obtained by the FISRE method are in a reasonable qualitative agreement with the values obtained by potentiometry/NMR (Table 1) if errors naturally accompanying utilization of trace concentrations and very high absolute values of the constants are taken into account.

The results show that the method can be used for fast screening of complex stabilities as it works with significantly lower amounts of compounds in comparison with common techniques such as potentiometry or NMR. Further, it could also be used for studying “problematic” metal ions (*e.g.* trivalent or tetravalent metal ions) or ligands. It can be used for a qualitative evaluation of metal ion–ligand interactions at the trace level. In addition, the FISRE method is more easy to carry out, faster and operationally cheaper than the “standard” methods (here, the stability constant of the $[Sc(DO3AP)]^{2-}$ complex cannot be determined by the conventional methods) and gives results which can be used for evaluation of the complexation ability of new ligands toward metal ions intended to be utilized in radiopharmaceuticals.

Labelling of the title ligands with generator- ($^{44}Ti/^{44}Sc$) and cyclotron-produced ($^{44m/44}Sc$) radios scandium

The labelling efficiency of the title ligands was tested at different solution pHs, temperatures and ligand concentrations (or more correctly, at different radiometal-to-ligand molar ratios). The labelling was done with no-carrier-added (NCA) radios scandium from two sources: ^{44}Sc eluted from a $^{44}Ti/^{44}Sc$ generator (finally obtained in 0.25 M aq. ammonium acetate buffer, pH 4)^{9,10} and a mixture of ^{44m}Sc and ^{44}Sc radioisotopes produced by an accelerator (finally obtained in 0.1 M aq. HCl)¹² as both sources can be considered for the future regular production of ^{44}Sc . The radios scandium from each source differs in the specific activity commonly obtained and/or in the cold metal ion impurity content. The labelling results are summarized in Table 3 and Fig. 6 and 7.

As the excess of a chelator over a metal radioisotope determines the accessible specific activity, the influence of the chelator/radios scandium molar ratio on the radiochemical yield was tested under conditions previously successfully used for DOTA derivatives: labelling time 30 min, pH 4 and temperature 70 °C. Results are presented in Table 3. With generator ^{44}Sc ,

Table 3 The ^{44}Sc labeling yields (in %) for DOTA and its monophosphorus acid analogues at different metal:ligand ratios. Experimental conditions: $t = 70$ °C, 30 min, pH = 4. All yields are given within the experimental uncertainties of the cyclone device of $\pm 5\%$

Radioisotope source	n_{ligand} (nmol)	Ligand			
		DOTA	DO3AP	DO3AP ^{PrA}	DO3AP ^{ABn}
Generator ^{44}Sc	1	10.1	10.0	8.6	1.9
	3	96.5	91.6	88.5	4.3
	5	96.7	93.8	95.7	20.8
	10	96.8	95.3	97.0	91.1
	20	97.3	95.7	97.1	94.7
	25	97.1	96.6	96.5	95.1
	30	97.6	97.6	97.7	96.6
Cyclotron $^{44m}Sc/^{44}Sc$	0.02	31.1	36.1	28.4	32.5
	0.07	97.8	97.4	88.3	90.6
	0.12	98.9	98.8	94.2	92.7
	0.17	99.4	98.8	98.9	94.7
	0.24	99.6	99.1	99.1	96.4






Fig. 6 Radiolabeling of DOTA (●) and its monophasic acid analogues (◇ DO3AP, ■ DO3AP^{ABn} and △ DO3AP^{PrA}) at different temperatures (pH 4.0, labelling time 30 min): (A) generator ^{44}Sc , $n(\text{ligand}) = 20 \text{ nmol}$; $n(\text{Sc}) = 4.5 \times 10^{-5}$ to $1 \times 10^{-4} \text{ nmol}$; $A(^{44}\text{Sc}) = 3 \text{ kBq}$. (B) Cyclotron $^{44\text{m}}\text{Sc}/^{44}\text{Sc}$, $n(\text{ligand}) = 0.2 \text{ nmol}$; $n(\text{Sc}) = 1.5 \times 10^{-6} \text{ nmol}$; $A(^{44}\text{Sc}) = 3 \text{ kBq}$.




Fig. 7 Radiolabelling of DOTA (●) and its monophasic acid analogues (◇ DO3AP, ■ DO3AP^{ABn} and △ DO3AP^{PrA}) at different pH values ($t = 70 \text{ }^\circ\text{C}$, labelling time 30 min): (A) generator ^{44}Sc , $n(\text{ligand}) = 20 \text{ nmol}$; $n(\text{Sc}) = 4.5 \times 10^{-5}$ to $1 \times 10^{-4} \text{ nmol}$; $A(^{44}\text{Sc}) = 3 \text{ kBq}$. (B) Cyclotron $^{44\text{m}}\text{Sc}/^{44}\text{Sc}$, $n(\text{ligand}) = 0.2 \text{ nmol}$; $n(\text{Sc}) = 1.5 \times 10^{-6} \text{ nmol}$; $A(^{44}\text{Sc}) = 3 \text{ kBq}$.

overall radiolabelling yields for ^{44}Sc -DOTA and ^{44}Sc -DO3AP were quite similar ranging from 10% to 95% if 1 or 5 nmol of the ligand, respectively, were added. In contrast, the radio-

labeling yield for ^{44}Sc -DO3AP^{ABn} was much lower (approx. 25% if <10 nmol of DO3AP^{ABn} was used) and 20 nmol of the ligand was required to reach 95% radiolabelling. With the cyclotron $^{44\text{m}}/^{44}\text{Sc}$, the amount of the ligands required to reach the same radiolabelling yields was significantly lower, although the same general trend was observed. Thus, 0.2 nmol of the ligands is enough for the cyclotron $^{44\text{m}}/^{44}\text{Sc}$ to obtain a minimum of 95% radiolabelling *versus* more than 5 nmol of the ligands for the ^{44}Sc from the $^{44}\text{Tl}/^{44}\text{Sc}$ generator. The differences between the radioscandium from the two sources could be explained by the different contents of cold metallic impurities competing with the ligands for the scandium radioisotope.

Specific activity (SA), a measure of the radioactivity per unit mass of the compound, is one of the major criteria for radiopharmaceuticals and should be as high as possible. Specific activities of the radioscandium from each source and for each ligand were calculated and the values are summarized in Table S3.† The calculated specific activity of the cyclotron $^{44\text{m}}/^{44}\text{Sc}$ is always higher than 10 MBq nmol^{-1} (4 h after end of beam). However for the generator ^{44}Sc , the specific activity was estimated to be max. $\sim 2 \text{ MBq nmol}^{-1}$ (for DOTA; 4 h after the end of elution).

The influence of temperature and solution pH was tested under conditions suggested by the experiments above: 20 nmol and 0.2 nmol of the ligands for the generator ^{44}Sc and the cyclotron $^{44\text{m}}/^{44}\text{Sc}$, respectively, and at a reaction time of 30 min. The results are plotted in Fig. 6. At 40 °C, the generator ^{44}Sc revealed 30% labeling for DO3AP whereas 5–8% yield was achieved for the other ligands. The yields increased with temperature as expected, to more than 90% and 95% at 70 °C and 90 °C, respectively, but with no difference among the ligands. Surprisingly at low temperatures, the labelling yield with DOTA was significantly lower than that with DO3AP. On the other hand with the cyclotron $^{44\text{m}}/^{44}\text{Sc}$, even if concentrations of the ligands were much lower compared to those for the generator ^{44}Sc , higher radiolabelling yields, mainly at lower temperatures, were obtained. At 40 °C (a temperature still suitable for antibody labelling), radiolabelling yields >40% (^{44}Sc -DO3AP^{ABn}), >55% (^{44}Sc -DO3AP) and $\sim 70\%$ (^{44}Sc -DOTA) were observed; the values for DOTA agreed well with those previously published.⁸ Complete binding (>95%) was achieved at 70 °C for all ligands. Thus, replacement of an acetate group on the DOTA skeleton does not lead to noticeably improved radiolabelling at lower temperatures if compared with the parent DOTA. Monophosphinate ligands were labelled worse than DOTA or DO3AP at lower temperatures.

The influence of solution pH was investigated in the range 2–6 and results are shown in Fig. 7. For radioscandium from both sources, the best labelling was observed at pH 4–5 with some decrease at a higher pH, probably due to the formation of colloidal scandium(III)-hydroxide species, as found in the previous studies.^{9,10} When the solution pH was reduced to 2, labelling efficiency significantly decreased for all the ligands but more for the phosphorus acid DOTA analogues. It is in agreement with the equilibrium data (see above) as monophos-



phorus acid DOTA analogs form the *out-of-cage* complexes with higher abundances than DOTA does. So, the optimal radiolabeling yields were achieved using facile conditions – pH 4, reaction time 30 min, and incubation temperature 70 °C.

Unlike for Ln(III) ions,^{37–40} labelling with ⁴⁴Sc was not improved. As discussed above, the formation of metal ion complexes of DOTA-like ligands is a two-step process,^{41,53} *i.e.* formation of the *out-of-cage* complex is followed by proton removal from, and metal ion transfer into, the ligand cavity as a rate-determining step. Both steps should be optimized to improve labelling efficiency. Here, the basicity of ring nitrogen atoms is similar in all investigated ligands leading to the similar labelling efficiency. In addition, small Sc(III) ions may not fit well into the cavity of the title ligands. A somewhat better labelling with DO3AP might be connected with the rather hard character of the phosphonate group leading to a good interaction with small and hard Sc(III) ions. The effect of the right combination of cavity size, basicity of ring amines and suitable properties of pendant donor atoms for efficient formation of the *out-of-cage* complex has been shown for phosphinic acid NOTA analogues. Very small trivalent gallium perfectly fits the small cavity of NOTA-like ligands, hard phosphinates are very selective for hard Ga(III) ions and they also decrease the ring amine basicity. It all leads to a very efficient labelling of these ligands with ⁶⁸Ga.⁴²

In vitro and *in vivo* studies

Even the labelling studies with the monophosphorus acid DOTA analogs did not show improved properties; *in vitro*/*in vivo* properties of their ^{44m/44}Sc complexes were evaluated. The serum stability can be seen as a benchmark of the behaviour of compounds in an extracellular environment and provides information on possible pathways by which the radiopharmaceutical in question can be demetallated.⁴⁹ It is well known that phosphonate-containing compounds may have a high affinity to bone and sorption on hydroxyapatite (HA), as an *in vitro* model material of bone, was also investigated. Challenging studies against either hydroxyapatite, or rat serum were monitored as a function of time and are presented in Fig. S6.† It was observed that ⁴⁴Sc–DO3AP, ⁴⁴Sc–DO3AP^{ABn} and ⁴⁴Sc–DO3AP^{PrA} complexes were stable over several hours in serum, similarly to ⁴⁴Sc–DOTA. It is also in accordance with previous studies on radiolanthanide complexes of DO3AP^{ABn} and DO3AP^{PrA}.^{39,40} Therefore, ligands with a DOTA-like structure seem to be good chelators for Sc(III) forming stable complexes. Negligible sorption of all complexes, even that of ⁴⁴Sc–DO3AP, on HA shows that no bone uptake should be expected after intravenous applications.

To better prove that ⁴⁴Sc–DO3AP (as the best ligand in the investigated series) has no uptake on bone, its biodistribution was investigated in healthy rats and the results are shown in Fig. 8 and Table S4.† These data show no specific uptake and rapid clearance through urine. The PET image confirmed this




Fig. 8 Biodistribution of ⁴⁴Sc–DO3AP in healthy Wistar rats ($n = 4$, 1 h p.i.).

observation. Thus, the ⁴⁴Sc remains in the chelate *in vivo* and the ⁴⁴Sc–DO3AP complex is not adsorbed on bone.

Conclusions

The DOTA derivatives bearing one methylphosphonic/phosphinic acid pendant arm, DO3AP, DO3AP^{PrA} and DO3AP^{ABn}, were evaluated as chelators for trivalent scandium. As expected, stability constants with Sc(III) are several orders of magnitude higher than those for trivalent lanthanides. Thermodynamic stability constants were also examined by the FISRE method. The method gave qualitatively similar results but it has an advantage over the common method that, as it is based on trace amounts of metal ions, it can be used for several radio-metal ions where conventional methods for stability constant determination can be hardly implemented. Such metal ions of potential radiopharmaceutical interest include *e.g.* easily hydrolyzing metal ions as Zr(IV), Bi(III), Ac(III) or Th(IV). In addition, experimental conditions of the method are more close to the real ones used for the preparation of radiopharmaceuticals.

The labelling efficiency of DOTA and its analogues was, for the first time, investigated on radioscandium from two sources, generator- or cyclotron-produced ⁴⁴Sc. Chelator excess over radioscandium necessary for efficient labelling was higher for the generator ⁴⁴Sc. The difference might be attributed to various amounts of cold metal impurities in radioscandium from each source as cold metal ions compete with radiometals during radiolabelling.⁵⁶ The best labelling conditions for DO3AP, DO3AP^{ABn} and DO3AP^{PrA} were the same as for DOTA. The phosphonate ligand, DO3AP, showed somewhat better labelling efficiency at low temperatures and it is a hint for possible future ligand designs. The specific activity after labelling was higher for the cyclotron produced ^{44m/44}Sc (~10 MBq nmol⁻¹) as compared to that for the generator produced ⁴⁴Sc (~2 MBq nmol⁻¹). *In vitro* stability of the Sc(III) complexes is very high as expected for complexes of macrocyclic ligands. No specific uptake and a rapid urine clearance of ⁴⁴Sc–DO3AP were observed in healthy rats. Slow formation kinetics remains



the main challenge in the design of chelators for scandium and lanthanide radioisotopes.

Acknowledgements

We thank the French–Czech travel grant (Barrande PHC 21934B) and PICS-CNRS 5196 (to R. K., C. A., and S. H.), the Grant Agency of the Czech Republic (13-08336S; to M. P., J. H., V. K., and P. H.) for financial support. The work was done in the frame of TD1004 COST Action. The ARRONAX cyclotron is a project promoted by the Regional Council of Pays de la Loire financed by local authorities, the French government and the European Union. This work was also supported by grants from the Pays de la Loire Council “Nucléaire pour la Santé” (NucSan) and from the French National Agency for Research called “Investissements d’Avenir” no. ANR-11-LABX-0018-01.

References

- 1 F. Rösch and R. P. Baum, *Dalton Trans.*, 2011, **40**, 6104–6111.
- 2 K. L. Kolsky, V. Joshi, L. F. Mausner and S. C. Srivastava, *Appl. Radiat. Isot.*, 1998, **49**, 1541–1549.
- 3 M. Polosak, A. Kasperek, S. Krajewski and A. Bilewicz, *J. Radioanal. Nucl. Chem.*, 2013, **295**, 1867–1872.
- 4 C. Müller, M. Bunka, S. Haller, U. Köster, V. Groehn, P. Bernhardt, N. van der Meulen, A. Türlér and R. Schibli, *J. Nucl. Med.*, 2014, **55**, 1658–1664.
- 5 M. Mamtimin, F. Harmon and V. N. Starovoitova, *Appl. Radiat. Isot.*, 2015, **102**, 1–4.
- 6 J. T. Harris and V. N. Starovoitova, *Appl. Radiat. Isot.*, 2015, **97**, 188–192.
- 7 C. Grignon, J. Barbet, M. Bardiès, T. Carlier, J. F. Chatal, O. Couturier, J. P. Cussonneau, A. Faivre, L. Ferrer, S. Girault, T. Haruyama, P. Le Ray, L. Luquin, S. Lupone, V. Métivier, E. Morteau, N. Servagent and D. Thers, *Nucl. Instrum. Methods Phys. Res., Sect. A*, 2007, **571**, 142–145.
- 8 S. Huclier-Markai, R. Kerdjoudj, C. Alliot, A. C. Bonraisin, N. Michel, F. Haddad and J. Barbet, *Nucl. Med. Biol.*, 2014, **41**, e36–e43.
- 9 F. Rösch, *Curr. Radiopharm.*, 2012, **5**, 187–201.
- 10 (a) M. Pruszyński, N. S. Loktionova, D. V. Filosofov and F. Rösch, *Appl. Radiat. Isot.*, 2010, **68**, 1636–1641; (b) D. V. Filosofov, N. S. Loktionova and F. Rösch, *Radiochim. Acta*, 2010, **98**, 149–156.
- 11 S. Krajewski, I. Cydzik, K. Abbas, A. Bulgheroni, F. Simonelli, U. Holzwarth and A. Bilewicz, *Radiochim. Acta*, 2013, **101**, 333–338.
- 12 C. Alliot, R. Kerdjoudj, N. Michel, F. Haddad and S. Huclier-Markai, *Nucl. Med. Biol.*, 2015, **42**, 524–529.
- 13 J. Luo, R. Liu, L. Jiang, Z. Liu, G. Sun and S. Ge, *Radiochim. Acta*, 2013, **101**, 607–612.
- 14 M. Bostan and S. M. Qaim, *Phys. Rev. C: Nucl. Phys.*, 1994, **49**, 266–271.
- 15 S. Bailey, *Phys. Rev. C: Nucl. Phys.*, 1961, **123**, 579–582.
- 16 T. J. Wadas, E. H. Wong, G. R. Weisman and C. J. Anderson, *Chem. Rev.*, 2010, **110**, 2858–2902.
- 17 B. M. Zeglis and J. S. Lewis, *Dalton Trans.*, 2011, **40**, 6168–6195.
- 18 M. D. Bartholomä, *Inorg. Chim. Acta*, 2012, **389**, 36–51.
- 19 V. Carroll, D. W. Demoin, T. J. Hoffman and S. S. Jurisson, *Radiochim. Acta*, 2012, **100**, 653–667.
- 20 C. S. Cutler, H. M. Hennkens, N. Sisay, S. Huclier-Markai and S. S. Jurisson, *Chem. Rev.*, 2013, **113**, 858–883.
- 21 C. F. Ramogida and C. Orvig, *Chem. Commun.*, 2013, **49**, 4720–4739.
- 22 E. Price and C. Orvig, *Chem. Soc. Rev.*, 2014, **43**, 260–290.
- 23 (a) G. A. Melson and R. W. Stotz, *Coord. Chem. Rev.*, 1971, **7**, 133–160; (b) S. A. Cotton, *Polyhedron*, 1999, **18**, 1691–1715; (c) P. R. Meehan, D. R. Aris and G. R. Willey, *Coord. Chem. Rev.*, 1999, **181**, 121–145.
- 24 S. Huclier-Markai, A. Sabatie, S. Ribet, V. Kubiček, M. Paris, C. Vidaud, P. Hermann and C. S. Cutler, *Radiochim. Acta*, 2011, **99**, 653–662.
- 25 S. Krajewski, I. Cydzik, K. Abbas, A. Bulgheroni, F. Simonelli, U. Holzwarth and A. Bilewicz, *Radiochim. Acta*, 2013, **101**, 333–338.
- 26 A. Majkowska-Pilip and A. Bilewicz, *J. Inorg. Biochem.*, 2011, **105**, 313–320.
- 27 M. Pruszyński, A. Majkowska-Pilip, N. S. Loktionova, E. Eppard and F. Rösch, *Appl. Radiat. Isot.*, 2012, **70**, 974–979.
- 28 E. Koumariou, N. S. Loktionova, M. Fellner, F. Rösch, O. Thews, D. Pawlak, S. C. Archimandritis and R. Mikolajczak, *Appl. Radiat. Isot.*, 2012, **70**, 2669–2676.
- 29 R. Hernandez, H. F. Valdovinos, Y. Yang, R. Chakravarty, H. Hong, T. E. Barnhart and W. Cai, *Mol. Pharmaceutics*, 2014, **11**, 2954–2961.
- 30 L. Moghaddam-Banaem, A. R. Jalilian, M. R. Pourjavid, E. Radfar, A. Bahrami-Samani, K. Yavari, M. Mazidi and M. Ghannadi-Maragheh, *Radiochim. Acta*, 2012, **100**, 215–221.
- 31 R. Chakravarty, S. Goel, H. F. Valdovinos, R. Hernandez, H. Hong, R. J. Nickles and W. Cai, *Bioconjugate Chem.*, 2014, **25**, 2197–2204.
- 32 S. Eigner, D. R. Beckford-Vera, M. Fellner, N. S. Loktionova, M. Piel, O. Lebeda, F. Rösch, T. L. Roß and K. Eigner-Henke, *Mol. Imaging Biol.*, 2013, **15**, 79–86.
- 33 C. Müller, M. Bunka, J. Reber, C. Fischer, K. Zhernosekov, A. Türlér and R. Schibli, *J. Nucl. Med.*, 2013, **54**, 2168–2174.
- 34 M. Pniok, V. Kubiček, J. Havlíčková, J. Kotek, A. Sabatie-Gogová, J. Plutnar, S. Huclier-Markai and P. Hermann, *Chem. – Eur. J.*, 2014, **20**, 7944–7955.
- 35 I. Lukeš, J. Kotek, P. Vojtišek and P. Hermann, *Coord. Chem. Rev.*, 2001, **216&217**, 287–312.
- 36 P. Táborský, P. Lubal, J. Havel, J. Kotek, P. Hermann and I. Lukeš, *Collect. Czech. Chem. Commun.*, 2005, **70**, 1909–1942.
- 37 M. Försterová, I. Svobodová, P. Lubal, P. Táborský, J. Kotek, P. Hermann and I. Lukeš, *Dalton Trans.*, 2007, 535–549.



- 38 P. Táborský, I. Svobodová, P. Lubal, Z. Hnatejko, S. Lis and P. Hermann, *Polyhedron*, 2007, **26**, 4119–4130.
- 39 M. Försterová, M. Petřík, A. Lázníčková, M. Lázníček, P. Hermann, I. Lukeš and F. Melichar, *Appl. Radiat. Isot.*, 2009, **67**, 21–29.
- 40 S. Lacerda, F. Marques, P. Campello, L. Gano, V. Kubíček, P. Hermann and I. Santos, *J. Labelled Compd. Radiopharm.*, 2010, **53**, 36–43.
- 41 J. Šimeček, P. Hermann, J. Havlíčková, E. Herdtweck, T. G. Kapp, N. Engelbogen, H. Kessler, H.-J. Wester and J. Notni, *Chem. – Eur. J.*, 2013, **19**, 7748–7757.
- 42 J. Notni, P. Hermann, J. Havlíčková, J. Kotek, V. Kubíček, J. Plutnar, N. S. Loktionova, P. J. Riss, F. Rösch and I. Lukeš, *Chem. – Eur. J.*, 2010, **16**, 7174–7185.
- 43 J. Notni, J. Šimeček and H.-J. Wester, *ChemMedChem*, 2014, **9**, 1107–1115.
- 44 J. Rudovský, P. Cígler, J. Kotek, P. Hermann, P. Vojtíšek, I. Lukeš, J. A. Peters, L. V. Elst and R. N. Muller, *Chem. – Eur. J.*, 2005, **11**, 2375–2384.
- 45 J. Rudovský, J. Kotek, P. Hermann, I. Lukeš, V. Mainero and S. Aime, *Org. Biomol. Chem.*, 2005, **3**, 112–117.
- 46 V. Kubíček, J. Havlíčková, J. Kotek, G. Tircsó, P. Hermann, É. Tóth and I. Lukeš, *Inorg. Chem.*, 2010, **49**, 10960–10969.
- 47 M. Kývala and I. Lukeš, Chemometrics '95, in *Abstract book*, Pardubice, Czech Republic, 1995, p. 63. Full version of the OPIUM program package is available at <http://www.natur.cuni.cz/~kyvala/opium.html>.
- 48 G. A. Kirakosyan, V. P. Tarasov and Yu. A. Buslaev, *Magn. Reson. Chem.*, 1989, **27**, 103–111.
- 49 W. C. Cole, S. J. DeNardo, C. F. Meares, M. J. McCall, G. L. DeNardo, A. L. Epstein, H. A. Obrien and M. K. Moi, *J. Nucl. Med.*, 1987, **28**, 83–90.
- 50 F. Benetollo, G. Bombieri, L. Calabi, S. Aime and M. Botta, *Inorg. Chem.*, 2003, **42**, 148–157.
- 51 K. L. Nash, *J. Alloys Compd.*, 1997, **249**, 33–40.
- 52 Z. Piskula, I. Svobodová, P. Lubal, S. Lis, Z. Hnatejko and P. Hermann, *Inorg. Chim. Acta*, 2007, **360**, 3748–3755.
- 53 (a) S. L. Wu and W. Horrocks Jr., *Inorg. Chem.*, 1995, **34**, 3724–3732; (b) A. Stenson, A. L. Thompson and D. Parker, *Dalton Trans.*, 2006, 3291–3293; (c) P. Vojtíšek and J. Rohovec, *Collect. Czech. Chem. Commun.*, 2006, **71**, 264–278; (d) P. Vojtíšek, J. Rohovec and J. Klimentová, *Eur. J. Inorg. Chem.*, 2008, 3948–3956.
- 54 J. Shubert, *J. Phys. Chem.*, 1948, **62**, 340–343.
- 55 (a) D. Jurkin, F. J. Gildehaus and B. Wierczinski, *Anal. Chem.*, 2007, **79**, 9420–9426; (b) D. Jurkin and B. Wierczinski, *J. Radioanal. Nucl. Chem.*, 2008, **277**, 91–96; (c) D. Jurkin, F. J. Gildehaus and B. Wierczinski, *J. Labelled Compd. Radiopharm.*, 2009, **52**, 33–40.
- 56 W. A. P. Breeman, M. de Jong, T. J. Visser, J. L. Erion and E. P. Krenning, *Eur. J. Nucl. Med.*, 2003, **30**, 917–920.

